Advisory Council on Blood Stem Cell Transplantation, 104550 [2024-30604]
Download as PDF
<![CDATA[
104550
Federal Register / Vol. 89, No. 246 / Monday, December 23, 2024 / Notices
The reorganization will improve
FDA’s ability to carry out its public
health mission by realigning and
dedicating resources within the
organization to modernize clinical trials.
The clinical trial innovation work tracks
will place DCI at the forefront to
robustly meet policy development,
implementation, and analysis needs in
areas such as Artificial Intelligence (AI),
Digital Health Technologies (DHTs),
Real-World Evidence (RWE), and other
rapidly advancing sectors in the
dynamic clinical trial ecosystem.
The CDER, OMP, Office of Medical
Policy Initiatives retitled the Division of
Clinical Trial Quality to the Division of
Clinical Innovations.
The reorganization will enhance the
office’s ability to attract and retain a
diverse workforce representative of our
nation and bring like scientists and
policy experts together from across the
organization, thereby facilitating
collaboration and efficient use of shared
resources while advancing key
innovations in drug development. By
developing responsive policies, the
Division of Clinical Innovations will
modernize the policy environment to
ensure that CDER is providing the
needed regulatory perspective to guide
the appropriate use of such tools and
technologies.
The FDA’s CDER, OMP has been
restructured as follows:
DCDH ORGANIZATION. The CDER
OMP (DCDH) is headed by the Director,
OMP and includes the following:
Office of Medical Policy (DCDH)
Office of Prescription Drug Promotion
(DCDHA)
Division of Advertising and Promotion
Review II (DCDHAA)
Division of Advertising and Promotion
Review I (DCDHAB)
Division of Promotion Policy, Research
and Operations (DCDHAC)
Office of Medical Policy Initiatives
(DCDHB)
Division of Medical Policy Development
(DCDHBA)
Division of Medical Policy Programs
(DCDHBB)
Division of Clinical Innovations
(DCDHBC)
khammond on DSK9W7S144PROD with NOTICES
II. Delegations of Authority
Pending further delegation, directives,
or orders by the Commissioner of Food
and Drugs, all delegations and
redelegations of authority made to
officials and employees of affected
organizational components will
continue in them or their successors
pending further redelegations, provided
they are consistent with this
reorganization.
VerDate Sep<11>2014
17:03 Dec 20, 2024
Jkt 265001
III. Electronic Access
This reorganization is reflected in
FDA’s Staff Manual Guide (SMG).
Persons interested in seeing the
complete Staff Manual Guide can find it
on FDA’s website at: https://
www.fda.gov/AboutFDA/
ReportsManualsForms/
StaffManualGuides/default.htm.
Authority: 44 U.S.C. 3101.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2024–30333 Filed 12–20–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Council on Blood Stem Cell
Transplantation
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
In accordance with the
Federal Advisory Committee Act, this
notice announces that the Secretary’s
Advisory Council on Blood Stem Cell
Transplantation (ACBSCT or Council)
has scheduled a public meeting.
Information about ACBSCT and the
agenda for the meeting can be found on
the ACBSCT website at https://
bloodstemcell.hrsa.gov/about/advisorycouncil.
DATES: Thursday, January 23, 2025, 3:00
p.m.–5:00 p.m. Eastern Standard Time.
ADDRESSES: This meeting will be held
virtually by webinar. A link to register
and join the meeting will be posted at
least 10 days prior to the meeting at
https://bloodstemcell.hrsa.gov/about/
advisory-council.
FOR FURTHER INFORMATION CONTACT:
Shelley Tims Grant, Designated Federal
Official, Division of Transplantation,
Health Systems Bureau, HRSA, 5600
Fishers Lane, 8W–67, Rockville,
Maryland 20857; 301–443–8036; or
ACBSCTHRSA@hrsa.gov.
SUPPLEMENTARY INFORMATION: ACBST
provides advice and recommendations
to the Secretary of HHS (Secretary) on
policy, program development, and other
matters of significance concerning the
activities under the authority of 42
U.S.C. 274k (Section 379 of the Public
Health Service Act), Public Law 109–
129, as amended. The Council may
transmit its recommendations through
the Administrator of HRSA on matters
related to the activities of the C.W. Bill
SUMMARY:
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Young Cell Transplantation Program
and National Cord Blood Inventory.
The agenda for the January 23, 2025,
meeting is being finalized and may
include the following topics: graft
versus host disease and late effects,
strategies for selecting cord blood units
for transplantation, HHS’ approach for
reviewing the state of the science and
recommendations on the
appropriateness of the inclusion of adult
stem cells and birthing tissues as new
types of therapies in the C.W. Bill
Young Cell Transplantation Program,
and other areas to increase blood stem
cell donation and transplantation.
Agenda items are subject to change as
priorities dictate. Refer to ACBSCT’s
website for any updated information
concerning the meeting. Members of the
public will have the opportunity to
provide comments. Public participants
may submit written statements in
advance of the scheduled meetings; oral
comments will be honored in the order
they are requested and may be limited
as time allows. Requests to submit a
written statement or make oral
comments to ACBSCT should be sent to
Shelley Tims Grant, using the contact
information above at least 3 business
days prior to the meeting. Individuals
who plan to attend and need special
assistance or other reasonable
accommodations should notify ACBSCT
at the address and phone number listed
above at least 10 business days prior to
the meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024–30604 Filed 12–20–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
Request for Public Comment: 60 Day
Notice for Extension of Fast Track
Generic Clearance for the Collection of
Qualitative Feedback on Agency
Service Delivery: Indian Health Service
Customer Service Satisfaction and
Similar Surveys
Indian Health Service, HHS.
Notice and request for
comments. Request for extension of
approval.
AGENCY:
ACTION:
In compliance with the
Paperwork Reduction Act of 1995, the
Indian Health Service (IHS) invites the
general public to take this opportunity
to comment on the information
collection Office of Management and
Budget (OMB) Control Number 0917–
SUMMARY:
E:\FR\FM\23DEN1.SGM
23DEN1
]]>Agencies
[Federal Register Volume 89, Number 246 (Monday, December 23, 2024)]
[Notices]
[Page 104550]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30604]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Advisory Council on Blood Stem Cell Transplantation
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, this
notice announces that the Secretary's Advisory Council on Blood Stem
Cell Transplantation (ACBSCT or Council) has scheduled a public
meeting. Information about ACBSCT and the agenda for the meeting can be
found on the ACBSCT website at https://bloodstemcell.hrsa.gov/about/advisory-council.
DATES: Thursday, January 23, 2025, 3:00 p.m.-5:00 p.m. Eastern Standard
Time.
ADDRESSES: This meeting will be held virtually by webinar. A link to
register and join the meeting will be posted at least 10 days prior to
the meeting at https://bloodstemcell.hrsa.gov/about/advisory-council.
FOR FURTHER INFORMATION CONTACT: Shelley Tims Grant, Designated Federal
Official, Division of Transplantation, Health Systems Bureau, HRSA,
5600 Fishers Lane, 8W-67, Rockville, Maryland 20857; 301-443-8036; or
[email protected].
SUPPLEMENTARY INFORMATION: ACBST provides advice and recommendations to
the Secretary of HHS (Secretary) on policy, program development, and
other matters of significance concerning the activities under the
authority of 42 U.S.C. 274k (Section 379 of the Public Health Service
Act), Public Law 109-129, as amended. The Council may transmit its
recommendations through the Administrator of HRSA on matters related to
the activities of the C.W. Bill Young Cell Transplantation Program and
National Cord Blood Inventory.
The agenda for the January 23, 2025, meeting is being finalized and
may include the following topics: graft versus host disease and late
effects, strategies for selecting cord blood units for transplantation,
HHS' approach for reviewing the state of the science and
recommendations on the appropriateness of the inclusion of adult stem
cells and birthing tissues as new types of therapies in the C.W. Bill
Young Cell Transplantation Program, and other areas to increase blood
stem cell donation and transplantation. Agenda items are subject to
change as priorities dictate. Refer to ACBSCT's website for any updated
information concerning the meeting. Members of the public will have the
opportunity to provide comments. Public participants may submit written
statements in advance of the scheduled meetings; oral comments will be
honored in the order they are requested and may be limited as time
allows. Requests to submit a written statement or make oral comments to
ACBSCT should be sent to Shelley Tims Grant, using the contact
information above at least 3 business days prior to the meeting.
Individuals who plan to attend and need special assistance or other
reasonable accommodations should notify ACBSCT at the address and phone
number listed above at least 10 business days prior to the meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024-30604 Filed 12-20-24; 8:45 am]
BILLING CODE 4165-15-P
